Actinium Pharmaceuticals, Inc. (Delaware) (ATNM) earnings
ATNM earnings moved a median of +1.02% by the close. Quarterly and annual ATNM reports and results, each read against the price at its own news timestamp. Back to the ATNM overview →
13 measured ATNM earnings events.
Where these ATNM earnings landedvs 12 measured ATNM earnings reactions
| Middle 50% of ATNM earnings reactions | -7.40% to +5.54% |
|---|---|
| Median reaction (to close) | +1.02% |
| Measured reactions | 12 |
Point-in-time · zero look-ahead
Half of the 12 ATNM earnings events with a measured close landed between -7.40% and +5.54%; 58% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Actinium Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | +0.00% | — | |
| Form 10-Q Actinium Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | -1.67% | +1.51% | |
| Form 10-K Actinium Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | +0.00% | +0.54% | |
| Form 10-Q Actinium Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | +0.00% | +5.07% | |
| Form 10-Q Actinium Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | -1.84% | -5.16% | |
| Form 10-Q Actinium Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | +3.33% | +3.33% | |
| Form 10-K Actinium Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | +0.31% | -6.88% | |
| Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024 | Press release | -2.53% | -8.97% | |
| Form 10-Q Actinium Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | +1.17% | -9.64% | |
| Form 10-Q Actinium Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | +18.18% | +21.61% | |
| Form 10-Q Actinium Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | +1.45% | +6.96% | |
| Form 10-K Actinium Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | +5.98% | +9.32% | |
| Form 10-Q Actinium Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | +2.00% | -16.58% |
Keep exploring
More ATNM: analyst actions → · SEC filings → · ATNM overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Second Sight Medical Products, Inc. (EYES) | 788 | -0.56% | 34% |
| bluebird bio, Inc. (BLUE) | 787 | -0.01% | 46% |
| Heat Biologics, Inc. (HTBX) | 781 | -0.40% | 41% |
| HEMISPHERX BIOPHARMA (HEB) | 779 | -0.06% | 42% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.